|[September 16, 2020]
The Patient Equation, a New Book by Medidata co-CEO Glen de Vries, Explores How the Digital Revolution Is Making Precision Medicine a Reality
The Patient Equation: The Precision Medicine Revolution (News - Alert) in the Age of COVID-19 and Beyond by Glen de Vries, the co-founder and co-CEO of Medidata, a Dassault Systèmes company, was released today by Wiley Publishers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005446/en/
The Patient Equation, by Glen de Vries (Photo: Business Wire)
The Patient Equation chronicles how the breakthroughs in new data-driven approaches to treatment, and the algorithms working in the background, are increasing our understanding of disease at both molecular and holistic, patient levels. De Vries helped to invent the cloud-based, end-to-end platform for clinical research used by pharmaceutical and biotechnology companies around the world. His insights into past innovations and current challenges formulate practical business techniques that will allow companies to deliver solutions faster, cheaper and more successfully.
"For the first time in our history, we have the ability to collect and organize vast amounts of data in real time, including clinical, 'omic', cognitive, and behavioral information. We have the opportunity to generate new evidence and insights, and ultimately deliver better treatments to more patients, for more conditions, at exactly the right time," said de Vries. "We have been tracking and treating diseases in a single dimension for too long. But what if we take a multidimensional view? Can we diagnose and treat patients more effectively, and can we produce more effective and safer therapies by combining, and looking beyond, traditional information sources? That's the essence of a patient equation - more and more diverse data will power the algorithms necessary for precise, personalized medicine."
As a result of breakthroughs in data analysis, we stand on the verge of a life science industry powered not by trial and error, but by a constant cycle of experimental evidence that begins in the laboratory; moves into clinical trial settings; and expands through analysis of the broad population. Each cycle will bring new insights, new applications, new refinements, and new successes. This has never been more important than during the current global pandemic.
"The challenges posed by COVID-19 are heralding changes in healthcare, health delivery, and fueling innovation in the field of virtualized clinical trials that incorporate new evidence models," de Vries added. "In order to propel health forward on all fronts and make precision medicine a reality, it's imperative to adjust our mindset and create new approaches to both research, data acquisition, and caregiving."
The Patient Equation highlights the revolution occurringat the intersection of biological and technological advancements, including:
How COVID-19 is putting a spotlight on the fragility of the healthcare system, and is helping accelerate the development of digital, patient-centric technologies that integrate data and data sharing
How the unexpected potential of a smartphone, smartwatch and other wearables are changing the future of diagnostics and treatments
How artificial intelligence (AI) can leverage clinical information from one therapeutic area or disease to find treatments for another, incorporating diverse and surprising sources of information into predictive models
De Vries is donating all royalties from The Patient Equation to the Conquer Cancer Foundation. More information about the book may be found at Medidata Institute / Patient Equation.
Medidata is a wholly owned subsidiary of Dassault Systèmes (News - Alert), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Glen de Vries
Glen de Vries is co-founder and co-CEO of Medidata, the most-used platform for clinical trials around the world. Medidata has powered tens of thousands of clinical trials, with millions of patients and billions of patient records. In 2019, in one of the largest healthcare technology acquisitions in history, Medidata became part of Dassault Systèmes. Glen has been driving Medidata's mission since the company's inception in 1999, "powering smarter treatments and healthier people" by advancing pharmaceutical business transformation with technology, non-traditional ways of thinking, and industry collaboration. Glen's publications have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, and other journals. He serves as a trustee of Carnegie Mellon University, and is the author of The Patient Equation (Wiley Publishing, 2020).
Glen received his undergraduate degree in molecular biology and genetics from Carnegie Mellon University, worked as a research scientist at the Columbia Presbyterian Medical Center, and studied computer science at New York University's Courant Institute of Mathematics. You can follow him on Twitter (News - Alert) at @CaptainClinical.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,500 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.
3DEXPERIENCE, the Compass (News - Alert) icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French "société européenne" (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
View source version on businesswire.com:
[ Back to the Next Generation Communications Community's Homepage ]